Skip To Main Content
Lilly
Menu closed
Lilly

    Immunology Journal Publications

    This page includes links to Lilly sponsored clinical trials that have been published in peer reviewed journals over the last 3 years. Each section is sorted by product and may be expanded by each phase. The list of publications below is limited to products that have been approved for use and may contain information about doses, delivery devices, uses, formulations and populations different from product labeling. Clinical decisions should be based on the full safety and efficacy information contained in the product's Full Prescribing Information in the provided link below.

    If you have questions about a Lilly study not listed below or would like to request an electronic copy of one of the journal publications on this page, please Contact Lilly services.

    Olumiant

    Full Prescribing Information

    Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis
    Published Date: January 22, 2019

    Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials
    Published Date: April 7, 2021
    Video Abstract Link
    Safety of baricitinib in East Asian patients with moderate-to-severe active rheumatoid arthritis: An integrated analysis from clinical trials
    Published Date: November 14, 2019
    Baricitinib for systemic lupus erythematosus – Authors' reply
    Published Date: February 2, 2019
    Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis
    Published Date: January 22, 2019
    MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis
    Published Date: January 15, 2019
    Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
    Published Date: July 21, 2018

    Two Phase 3 Trials of Baricitinib for Alopecia Areata
    Published Date: March 26, 2022
    Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials
    Published Date: April 7, 2021
    Video Abstract Link
    Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis
    Published Date: February 25, 2020
    Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials
    Published Date: January 29, 2020
    Safety of baricitinib in East Asian patients with moderate-to-severe active rheumatoid arthritis: An integrated analysis from clinical trials
    Published Date: November 14, 2019
    Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM
    Published Date: September 5, 2019
    Efficacy and safety of long-term baricitinib with and without methotrexate for the treatment of rheumatoid arthritis: experience with baricitinib monotherapy continuation or after switching from methotrexate monotherapy or baricitinib plus methotrexate
    Published Date: June 24, 2019
    Relative Impact of Pain and Fatigue on Work Productivity in Patients with Rheumatoid Arthritis from the RA-BEAM Baricitinib Trial
    Published Date: June 21, 2019
    Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial
    Published Date: June 12, 2019
    Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain
    Published Date: June 6, 2019
    Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis
    Published Date: May 10, 2019
    Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis
    Published Date: May 1, 2019
    Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy
    Published Date: April 19, 2019
    Use of daily electronic patient-reported outcome (PRO) diaries in randomized controlled trials for rheumatoid arthritis: rationale and implementation
    Published Date: March 22, 2019
    Efficacy and safety data based on historical or pre-existing conditions at baseline for patients with active rheumatoid arthritis who were treated with baricitinib
    Published Date: March 8, 2019
    Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials
    Published Date: February 20, 2019
    Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis
    Published Date: January 22, 2019
    Safety and Efficacy of Baricitinib in Patients Receiving Conventional Synthetic Disease-Modifying Antirheumatic Drugs or Corticosteroids
    Published Date: October 24, 2018
    Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment
    Published Date: September 15, 2018
    Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study
    Published Date: September 7, 2018
    Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study
    Published Date: August 4, 2018
    Characterization and Changes of Lymphocyte Subsets in Baricitinib-Treated Patients With Rheumatoid Arthritis
    Published Date: July 29, 2018
    Mean cost per number needed to treat of baricitinib versus adalimumab in the treatment of rheumatoid arthritis in Italy>
    Published Date: July 27, 2018
    Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs
    Published Date: May 8, 2018

    No Publication Journals

    Taltz

    Full Prescribing Information

    Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure
    Published Date: November 20, 2019
    Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis
    Published Date: January 4, 2019
    Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials
    Published Date: September 10, 2018

    Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis
    Published Date: January 4, 2019
    Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials
    Published Date: September 10, 2018
    Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis
    Published Date: April 11, 2018

    A subset analysis of efficacy and safety outcomes from phase 3 clinical studies of ixekizumab for the treatment of patients with severe plaque psoriasis
    Published Date: April 21, 2020
    Efficacious psoriasis treatment improves patients' work productivity
    Published Date: April 11, 2020
    Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials
    Published Date: March 21, 2020
    Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1)
    Published Date: February 7, 2020
    Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis
    Published Date: January 21, 2020
    Ixekizumab improves secondary lesional signs, pain and sexual health in patients with moderate-to-severe genital psoriasis
    Published Date: January 9, 2020
    Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial
    Published Date: December 5, 2019
    Candida Infections in Clinical Trials of Ixekizumab (Taltz), an Interleukin-17A Monoclonal Antibody, in Patients With Psoriasis or Psoriatic Arthritis
    Published Date: December 1, 2019
    Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure
    Published Date: November 20, 2019
    Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)
    Published Date: November 5, 2019
    Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses
    Published Date: November 4, 2019
    Video Abstract Link
    Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER -3 study
    Published Date: October 29, 2019
    Achievement of the National Psoriasis Foundation Treatment Targets With Ixekizumab: Pooled Analyses From Four Clinical Studies
    Published Date: September 25, 2019
    A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment
    Published Date: August 3, 2019
    Absolute and Relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes
    Published Date: July 29, 2019
    Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing Spondylitis
    Published Date: June 28, 2019
    Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial
    Published Date: February 25, 2019
    Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis
    Published Date: January 4, 2019
    Impact of Ixekizumab Treatment on Itch and Psoriasis Area and Severity Index in Patients with Moderate-to-Severe Plaque Psoriasis: An Integrated Analysis of Two Phase III Randomized Studies
    Published Date: November 21, 2018
    Ixekizumab Improved Patient-Reported Genital Psoriasis Symptoms and Impact of Symptoms on Sexual Activity vs Placebo in a Randomized, Double-Blind Study
    Published Date: November 15, 2018
    Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1)
    Published Date: November 1, 2018
    Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial
    Published Date: October 22, 2018
    Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors
    Published Date: October 20, 2018
    Blauvelt A, Gooderham M, Iversen L, et al. Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3).
    Published Date: October 1, 2018
    A statistical method to convert published response rates into marginal distributions with an example application in psoriasis
    Published Date: September 26, 2018
    Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials
    Published Date: September 10, 2018
    Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors
    Published Date: September 7, 2018
    Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients’ health-related quality of life and productivity
    Published Date: August 13, 2018
    Points to consider for analyzing efficacy outcomes in long-term extension clinical trials
    Published Date: July 26, 2018
    Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2
    Published Date: July 24, 2018
    Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study
    Published Date: July 2, 2018
    Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1)
    Published Date: June 25, 2018
    Efficacy and safety of ixekizumab in patients with plaque psoriasis across different degrees of disease severity: results from UNCOVER-2 and UNCOVER-3
    Published Date: June 12, 2018
    Exposure-Response Modeling to Characterize the Relationship Between Ixekizumab Serum Drug Concentrations and Efficacy Responses at Week 12 in Patients With Moderate to Severe Plaque Psoriasis
    Published Date: June 7, 2018
    Minimal clinically important difference (MCID ) for work productivity and activity impairment (WPAI ) questionnaire in psoriasis patients
    Published Date: May 30, 2018
    Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 study
    Published Date: May 25, 2018
    Ixekizumab Pharmacokinetics, Anti-Drug Antibodies, and Efficacy through 60 Weeks of Treatment of Moderate to Severe Plaque Psoriasis
    Published Date: May 11, 2018
    Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase III b study of patients with moderate-to-severe genital psoriasis
    Published Date: May 10, 2018

    Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis
    Published Date: January 21, 2020
    A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial
    Published Date: December 30, 2019
    Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure
    Published Date: November 20, 2019
    A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial
    Published Date: December 30, 2019
    Prevalence and outcome of latent tuberculosis in patients receiving ixekizumab: integrated safety analysis from 11 clinical trials of patients with plaque psoriasis
    Published Date: January 4, 2019
    Long-term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open-label, phase 3 study (UNCOVER -J)
    Published Date: October 16, 2018
    Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials
    Published Date: September 10, 2018

    Can't find what you're looking for? Contact us for answers to your medical questions.

    • Copyright
    • Terms of Use
    • Privacy Statement
    • Accessibility Statement
    • Sitemap
       

      This site is intended for US Healthcare Professionals only.

      4.0.2 03/2023 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2023. All rights reserved.

      Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

      Facebook Twitter LinkedIn
      Lilly